Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 14/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685204 | 0.88 | RIPK1 (0.43) | MAPKAPK5FYNMAPK10 | |
| SCHEMBL3868797 | 0.88 | AURKA (0.49) | MAPKAPK5 | |
| SCHEMBL2068700 | 0.87 | MAPKAPK5 (0.73) | MAPKAPK5FYNSYK | |
| SCHEMBL1685130 | 0.84 | MAPKAPK5 (0.77) | MAPKAPK5FYNMAPK10SYK | |
| SCHEMBL10134371 | 0.84 | MAPKAPK5 (0.75) | MAPKAPK5FYNMAPK10SYK | |
| SCHEMBL3875479 | 0.83 | TNIK (0.38) | MAPKAPK5 | |
| SCHEMBL3875061 | 0.82 | MAPKAPK5 (0.36) | MAPKAPK5MAPK10SYK | |
| SCHEMBL1685319 | 0.81 | JAK2 (0.36) | MAPKAPK5 | |
| SCHEMBL13922489 | 0.81 | FYN (0.52) | MAPKAPK5FYNMAPK10SYK | |
| SCHEMBL12618726 | 0.81 | MAPKAPK5 (0.51) | MAPKAPK5FYNMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885FYN 1030/4885MAPK10 486/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885FYN 1030/4885MAPK10 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.